News

BackgroundConduction system disorders and arrhythmias may require pacemaker (PM) or implantable cardioverter-defibrillator implantation in transthyretin amyloid…

AbstractImportance: In patients with transthyretin amyloid cardiomyopathy (ATTR-CM), acoramidis achieves near-complete (≥90%) transthyretin stabilization and…

Acoramidis (Attruby; BridgeBio Pharma), an oral transthyretin (TTR) stabilizer approved for transthyretin amyloid cardiomyopathy (ATTR-CM), significantly slowed the…

A generic medicine for hereditary transthyretin amyloidosis with cardiomyopathy could soon become more widely available in Europe.At its July 2026 meeting, the…

AbstractBackgroundTransthyretin amyloid cardiomyopathy (ATTR-CM) is more often diagnosed in men than in women but sex-specific data remain limited.ObjectivesThe…

The late-stage failure of AstraZeneca's Wainua (eplontersen) in the Phase 3 CARDIO-TTRansform trial is a first-in-class setback for TTR gene-silencing therapies in…

Alnylam Pharmaceuticals (ALNY) is up 3.6% today. Here is some analysis on what might have caused this price movement.Analysis: The move appears tied to a mix of…

DelveInsight's "AL Amyloidosis Market Insights, Epidemiology, and Market Forecast - 2036" report delivers an in-depth understanding of the AL amyloidosis,…

Patients with wild-type transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) who were alive 2 years after tafamidis initiation had a less advanced disease…

A type of cell damage called oxidative stress may be key to the development of disease symptoms in people who carry the most common TTR gene mutation that causes…